Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
BackgroundSecukinumab is a biologic disease-modifying antirheumatic drug (bDMARD) that has demonstrated efficacy in the treatment of axial spondyloarthritis (axSpA, i.e., ankylosing spondylitis and non-radiographic axSpA) across various clinical trials. However, data of secukinumab in clinical pract...
相似书籍
-
Corrigendum: Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
由: Francisca Sivera, et al.
出版: (2024-09-01) -
Effectiveness and safety of secukinumab in axial spondyloarthritis and psoriatic arthritis: A retrospective analysis of its real-world usage from India
由: Sham Santhanam, et al.
出版: (2020-01-01) -
Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
由: Juergen Braun, et al.
出版: (2023-05-01) -
Real-Life Data of Secukinumab in Patients with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis: Patient Baseline Characteristics Data from the PROMPT Study
由: Ploysyne Rattanakaemakorn, et al.
出版: (2024-11-01) -
Active pulmonary tuberculosis in a patient with secukinumab treatment
由: Cao Thanh Ngoc, MD, PhD, et al.
出版: (2023-01-01)